Welcome to our dedicated page for Definitive Healthcare SEC filings (Ticker: DH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding churn rates, data acquisition costs, or insider sentiment in Definitive Healthcare鈥檚 dense disclosures can feel like searching for a single ICD-10 code in a sea of claims. Stock Titan surfaces the signal you need鈥攆ast. Whether you鈥檙e tracking Definitive Healthcare insider trading Form 4 transactions or deciphering a 300-page MD&A, the complexity of a healthcare data-as-a-service model makes traditional document dives time-consuming.
Our platform solves that. AI parses every Definitive Healthcare quarterly earnings report 10-Q filing, highlights ARR growth, and links segment commentary to KPIs. AG真人官方-time alerts flag Definitive Healthcare Form 4 insider transactions real-time, while natural language summaries offer Definitive Healthcare SEC filings explained simply. You鈥檒l see side-by-side Definitive Healthcare earnings report filing analysis and peer comps without touching a spreadsheet.
What can you explore today?
- Growth metrics unlocked: our AI guides you in understanding Definitive Healthcare SEC documents with AI, extracting subscriber counts, retention rates, and data-licensing revenue deep inside footnotes.
- Governance clarity: the latest Definitive Healthcare executive stock transactions Form 4 and Definitive Healthcare proxy statement executive compensation filings reveal how leadership incentives align with market expansion.
- Event impact: receive instant context when a new partner agreement drops via an Definitive Healthcare 8-K material events explained alert.
- Year-end deep dives: get the Definitive Healthcare annual report 10-K simplified into bullet-ready takeaways in minutes.
From segment analytics to acquisition spend, Stock Titan鈥檚 AI turns Definitive Healthcare filings into actionable insight鈥攕o you can focus on decisions, not page counts.
Vital Farms, Inc. (VITL) Form 4 filing dated 07/03/2025 discloses that Executive Chairperson, Director and >10% owner Matthew Ohayer sold an aggregate 30,000 shares of common stock on 07/01/2025 under a previously adopted Rule 10b5-1 trading plan (established 03/14/2025).
The sales were split into two blocks:
- 9,714 shares at a weighted-average price of $38.85
- 20,286 shares at a weighted-average price of $39.32
Post-transaction ownership stands at 6,858,890 directly held shares plus 716,000 shares held by a former spouse over which the reporting person retains voting control but no economic interest. The direct sale represents roughly 0.4% of Mr. Ohayer鈥檚 direct stake, leaving him with a sizeable position that continues to exceed the 10% beneficial-ownership threshold.
No derivative security transactions were reported, and no earnings or operational data were included in this filing.
Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc., is offering Autocallable Barrier Securities maturing 6 July 2027 with a total face amount of $922,000 (1,000-denomination). The unsecured notes are linked to the worst performer of three U.S. equity indices: Nasdaq-100 (22,679.01), Russell 2000 (2,175.035) and S&P 500 (6,204.95).
Key mechanics: 1) Automatic early redemption on 30 Jun 2026 if every index closes at or above its initial level, paying principal plus a 12 % premium ($1,120). 2) If not called, final payout on 30 Jun 2027 depends solely on the worst performer: 鈥� Appreciation participates at a 300 % upside rate. 鈥� If the worst performer is 鈮� initial but 鈮� 70 % barrier, only principal is returned. 鈥� If it falls below the 70 % barrier, investors lose 1 % of principal for each 1 % decline, up to total loss.
The notes do not pay coupons, are not listed, and carry the credit risk of both CGMHI and Citi. Issue price is $1,000, but the internal estimated value is $980.60; underwriting fee up to $10 per note. CGMI will make a secondary market on a best-efforts basis only.
Risk highlights include potential total loss of investment, reliance on a single worst-performing index, high valuation sensitivity on only two observation dates, liquidity constraints, small-cap volatility in Russell 2000, and uncertain tax treatment. The modest offering size and routine structure suggest limited impact on Citi鈥檚 overall financials.
Definitive Healthcare Corp. (DH) 鈥� Form 3 filing
The filing records the initial beneficial ownership position of newly listed insider Jonathan Paris, who became Chief Legal Officer on 16 June 2025. According to the disclosure, Paris currently reports no direct or indirect ownership of DH securities. An Exhibit 24 Power of Attorney is included, authorising future Section 16 filings on his behalf. No derivatives, options, or other equity instruments are listed. The submission is made on an individual basis and bears a manual signature dated 18 June 2025.
Because no securities are owned and no transactions are reported, the document is largely administrative and carries minimal immediate financial impact for investors.
FAQ
What is the current stock price of Definitive Healthcare (DH)?
What is the market cap of Definitive Healthcare (DH)?
What is Definitive Healthcare Corp?
How does Definitive Healthcare generate revenue?
What types of healthcare providers are included in its data?
How does the DH platform aid in strategic planning?
What are some of the key product offerings of Definitive Healthcare?
Who are the typical clients of Definitive Healthcare?
How is data quality maintained on the platform?
How does Definitive Healthcare differentiate itself from competitors?
